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Abstract
Original Article
IntroductIon
Tuberculosis (TB) is still one of the most important infectious 
diseases in the world. Effective control of TB is achieved by 
early diagnosis and drug susceptibility testing for initiation 
of appropriate treatment.[1] Following streptomycin (STR) 
introduction as an anti‑TB agent in the late 1940s, drug‑resistant 
Mycobacterium tuberculosis was reported in a very short time. 
Even drug‑resistant TB was not taken into consideration until 
multidrug‑resistant‑TB (MDR‑TB) showed a big explosion 
in the USA and Europe 1990s.[2] MDR‑TB is defined as TB 
resistant at least to both isoniazid (INH) and rifampicin (RIF). 
MDR‑TB compared drug‑susceptible TB is a global health 
threat results from treatment and diagnosis difficulties.[3] 
Accurate and rapid diagnosis of drug‑resistance TB can provide 
early initiation of effective treatment and therefore reduce 
the spread of drug resistance and improve healing rate. 
Early and rapid diagnosis of TB and MDR‑TB is a global 
priority.[4] Colorimetric assays are based on the principle of 
color change of the indicator dye added to antibiotic‑containing 
and antibiotic‑free medium. M. tuberculosis bacilli change 
the color of medium by metabolizing the dye during growth. 
When compared with conventional antibiotic susceptibility 
testing, these assays give rapid and reliable results for 
detecting resistance.[5] One of these tests is the crystal violet 
decolorization assay (CVDA) based on the loss of color due 
to the reduction and sequestering the dye by living bacilli 
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in the medium.[1] In this multicenter study, we compared 
the performance of CVDA for susceptibility testing of M. 
tuberculosis to INH and RIF.
Methods
Study centers
The study was performed in 4 centers. A total of 24 isolates 
(19 clinical isolates and 5 standard strains) were tested at C1. 
Only one of these isolates was resistant to INH. All isolates 
were sensitive to RIF. In addition, five reference strains were 
used as controls in C1. In C2, 20 isolates were tested, including 
6 multidrug resistant (MDR), 2 INH resistant, and 11 INH and 
RIF susceptible isolates. One isolate excluded from the study 
due to contamination.
A total of 21 isolates and the reference strain H37Rv were 
tested in C3. One INH resistant and 1 RIF resistant isolate 
were excluded from the study due to lack of growth and a 
total of 19 isolates including 8 MDR, 1 INH resistant, and 10 
susceptible isolates were evaluated.
In the C4, 2 MDR isolates, 1 INH resistant isolate, 6 susceptible 
isolates, and H37Rv reference strain were tested. This 
multicenter study consisted of two phases (Phase I and II). 
The reference test method was Bactec Mycobacteria Growth 
Indicator Tube (MGIT) 960 in all centers. Ethical approval 
was not required for the study.
Preparation of crystal violet
Crystal violet (CV) stock solution was prepared in sterile 
distilled water and sterilized by filtration. Final concentration 
was adjusted to 25.0 μg/ml and solution kept on +4°C until 
used.[1,6]
Preparation of bacterial inoculums
Bacterial  inoculums were prepared from freshly 
grown on Lowenstein–Jensen media and the turbidity 
of the supernatant was adjusted to a McFarland No. 1 
standard.[1,6]
Preparation of test tubes with and without drugs for 
Phase I
In Phase I, all tubes were prepared as previously 
described.[6] Briefly, after preparation, 1 mL of 7H9S broth 
was dispensed into screw cap tubes. For each isolates, 3 tubes 
(tube 1; 0.125 μg/mL INH, tube 2; 0.50 μg/mL RIF and tube 
3; growth control) were used. All tubes were stored at +4°C 
until use (not exceed 1 month).
Preparation of test microplates for Phase II
All tests were performed in 96‑well microtiter plates. All 
wells were filled with 0.1 mL of Middlebrook 7H9S broth. 
Antibiotic test concentrations were prepared by the serial 
two‑fold dilution. Seven dilutions of each antibiotic and 
a growth control well were prepared for each isolate. The 
antibiotics concentrations were 2.00–0.03 μg/mL for INH and 
RIF, except C3 (2.00–0.06 μg/mL).All prepared microtiter 
plates were stored at −80°C until use.[7]
Performing the test
Phase I: An INH test tube (0.125 μg/mL), a RIF test tube 
(0.50 μg/mL), and a drug‑free growth control tube were used 
for each isolate. Fifty microliters of a bacterial suspension 
(McFarland no 1) was inoculated into the three tubes and 
the tubes were be incubated at 37°C. On the 5th or 7th day 
of incubation, 100 μl of CV stock solution (25.0 μg/mL) 
was then added to all tubes and incubated for an additional 
24–48 h. As CV (blue/purple) was decolorized by the growth 
of bacteria, the isolates were considered to be resistant to that 
drug if the color of CV was lost. If a color did not decolorize 
in the growth control tube, incubation was prolonged until 
decolorization [Figure 1]. Decolorization was measured the 
complete disappearance of blue color.[6]
Phase II: The bacterial suspension (McFarland no 1) was 
diluted at a 1:10 ratio and 100 μl of bacterial suspension 
was inoculated into each well. After bacterial inoculation, 
all plates were incubated at 37°C. On the 5th or 7th day of 
incubation, 25.0 μL of CV stock solution (25.0 mg/L) was 
added into all wells. After that incubation was continued 
until decolorization in the growth control well. Minimum 
inhibitory concentration (MIC) was defined as the lowest 
drug concentration without decolorization. If the MIC value 
was over the breakpoint value, the isolate was considered to 
be resistant to tested antibiotic [Figure 2]. Breakpoints values 
were 0.125 and 0.5 μg/mL for INH and RIF, respectively.[7]
results
C1: A total of 24 M. tuberculosis isolates were tested, including 
five reference strains and 19 clinical isolates. Tested reference 
strains of M. tuberculosis were ATCC 35822 (INH resistant), 
ATCC 35838 (RIF resistant), ATCC 35820 (STR resistant), ATCC 
35837 (ethambutol [ETM] resistant), and H37Rv (susceptible to 
anti‑TB drugs). Susceptibility testing of the isolates with primary 
anti‑TB drugs was performed by Bactec MGIT 960 as reference 
method, and one of these clinical isolates was resistant to INH, 
and the remaining 18 isolates were susceptible to INH and RIF.
In Phase I, ATCC 35822 M. tuberculosis and one clinical 
isolate were resistant to INH by both CVDA and reference 
Figure 1: (A) Growth control (decolorized). (B) Susceptible to 
isoniazid (not decolorize). (C) Susceptible to rifampicin (not decolorize)
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method. Others were identified susceptible to INH and RIF 
by both methods. The results were obtained on average of 
10 ± 0.78 days (9–11 days).
In Phase II, MIC values of INH in ATCC 35838, ATCC 35820, 
ATCC 35837, and H37Rv reference strains were ≤0.03 μg/mL; 
MIC of ATCC 35822 strain was ≥2.00 μg/mL. MIC values 
were determined ≤0.03 μg/mL in 10 isolates, 0.06 μg/mL in 
5 isolates, 0.125 μg/mL in 3 isolates, and ≥2.00 μg/mL in 1 
isolate. The MIC value of RIF for ATCC 35822, ATCC 35820, 
and H37Rv standard strains were 0.06 μg/mL; ≤0.03 μg/mL 
for ATCC 35837; and ≥2.00 μg/mL for ATCC 35838. The 
MIC values for RIF were found as ≤0.03 μg/mL for 5 isolates; 
0.03 μg/mL for 1 isolate; 0.06 for 5 isolates; and 0.125 μg/mL 
for 8 isolates. Results were obtained on the 8th day except for 
the ATCC 35838 strain that was obtained on the 10th day.
C2: Although 20 isolates were tested; 1 isolate was excluded 
from the study due to contamination. Drug susceptibility 
testing by MGIT 960 showed 6 MDR‑TB isolates, 2 resistant 
to INH, and the remaining 11 isolates were susceptible to 
both drugs.
In Phase I, 11 isolates were susceptible to INH and RIF by 
both methods. Two isolates were found resistant to INH and 
susceptible to RIF in two methods. Five out of six MDR 
isolates were defined MDR by CVDA. One isolate found 
RIF susceptible by CVDA whereas it was resistant by MGIT 
960. The results were obtained on average 10.1 ± 1.32 days 
(9–13 days).
In Phase II, MIC values of INH were ≤0.03 μg/mL for 
4 isolates, 0.03 μg/mL for 4 isolates, 0.06 μg/mL for 
3 isolates, 0.50 μg/mL for 2 isolates, 1.00 μg/mL for 
2 isolates, 2.00 μg/mL for 2 isolates, and ≥2.00 μg/mL for 
2 isolates. MIC values of RIF were detected as ≤0.03 μg/mL 
for 4 isolates, 0.03 μg/mL for 2 isolates, 0.06 μg/mL for 
5 isolates, 0.50 μg/mL for 2 isolates, 2.00 μg/mL for 2 isolates, 
and ≥2.00 μg/mL for 4 isolates. The results were obtained on 
average 12.05 ± 1.5 days (9–14 days).
C3: A total of 21 isolates and the H37Rv reference strain were 
tested, but decolorization was not observed in two isolates and 
they were excluded from the study due to lack of growth in 
Phase I and Phase II. For that reason, 19 isolates were evaluated 
in the study.
In Phase I, 8 MDR isolates, 1 INH resistant isolates, and 10 
drug‑susceptible isolates were tested. The results obtained by 
CVDA for INH and RIF were found in full agreement with 
the reference method MGIT 960. Results were obtained on 
average 13.8 ± 4.7 days (7–24 days) in the study.
In Phase II, MIC value of INH were found ≤0.06 μg/mL 
for 10 isolates, 0.125 μg/mL for 1 isolate, 0.25 μg/mL for 
2 isolates, 0.50 μg/mL for 2 isolates, 1.00 μg/mL for 1 isolate, 
and ≥2.00 μg/mL for 3 isolates. One isolate was determined 
as resistant to INH by MGIT 960, whereas it was susceptible 
by CVDA (MIC value was 0.125 μg/mL). MIC values of RIF 
were determined as ≤0.06 μg/mL in 11 isolates, 0.50 μg/mL 
in 2 isolates, 1.00 μg/mL in 2 isolates, and ≥2.00 μg/mL 
in 4 isolates. Two isolates were found resistant to RIF by 
MGIT 960, but it was susceptible by CVDA (MIC values 
were 0.50 μg/mL). Results were obtained on average 
10.3 ± 2.74 days (6–13 days).
C4: A total of 9 clinical isolates and one standard strain 
were tested. MGIT 960 was used as reference method for 
susceptibility testing of all isolates. Two isolates were resistant 
to both INH and RIF and one isolate was resistant to INH.
In Phase I, the results of the tested isolates were concordant 
for INH and RIF. Two isolates were resistant to INH and RIF 
and one isolate was resistant only to INH by CVDA and MGIT 
960. The other 6 isolates were susceptible to both drugs. In 
Phase I, results were obtained on the 9th day.
In Phase II, MIC values of INH were 0.015 μg/mL for 
5 isolates, 0.03 μg/mL for 2 isolates, 1.00 μg/mL for 2 isolates, 
and 2.00 μg/mL for 1 isolate. All results were concordant 
with MGIT 960. MIC values of RIF were 0.015 μg/mL for 
1 isolate, 0.06 μg/mL for 1 isolate, 0.125 μg/mL for 2 isolates, 
0.25 μg/mL for 1 isolate, 0.50 μg/mL for 1 isolate, 1.00 μg/mL 
for 2 isolates, 2.00 μg/mL for 1 isolate, and ≥2.00 μg/mL 
for 1 isolate. Two isolates were susceptible by MGIT 960, 
whereas they were determined as resistant by CVDA 
(MIC values were 1.00 and 2.00 μg/mL). In Phase II, results 
were obtained on the 9th day.
Evaluation of the results from all centers
In Phase I, the specificity, sensitivity, positive predictive 
value (PPV), negative predictive value (NPV), and agreement 
for INH were 100%, whereas they were 98.1%, 100%, 94.4%, 
100%, and 98.6% for RIF, respectively [Table 1].
In Phase II, specificity, sensitivity, PPV, NPV, and agreement 
for INH were 98%, 100%, 95.4%, 100%, and 98.6%, whereas 
they were 96.3%, 88.2%, 88.2%, 96.3%, and 94.4%, for RIF, 
Figure 2: A1‑5: Growth control (decolorized). Isolate 1, 2, and 3: Minimum 
inhibitory concentration value is G1, 2 and 3 (0.06 μg/ml). Isolate 4: 
Minimum inhibitory concentration value is ≥2.00 μg/ml (resistant). Isolate 
5: Minimum inhibitory concentration value is ≤0.03 μg/ml
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respectively [Table 2]. Results were obtained on average 
10.9 ± 3.1 days in Phase I and 9.8 ± 2.2 days in Phase II.
dIscussIon
Especially in low‑ and middle‑income countries, TB is still a 
major infectious disease with high morbidity and mortality.[8] 
In recent years, an increase in the prevalence of multidrug and 
extensively drug‑resistant TB has complicated TB control.[9]
Accurate, reliable, and rapid culture and susceptibility testing 
are prerequisites for a successful treatment regimen. Rapid 
detection of drug susceptibility acts as an important factor to 
prevent the spread of resistant isolates.[10]
Due to the increasing number of MDR‑TB cases in last years, 
there is an urgent need of rapid, reliable, and inexpensive drug 
susceptibility testing methods. Colorimetric‑based methods 
are faster than standard culture methods and it is also less 
expensive than molecular methods.[9] Many colorimetric 
methods such as the resazurin microtiter assay (REMA) or 
the resazurin tube assay, the malachite green decolorization 
assay (MGDA), the nitrate reductase assay (NRA), and the 
CVDA have been developed. These methods are reliable, rapid, 
inexpensive, safe and repeatable.[11‑18]
The first study of CVDA for antibiotic susceptibility testing 
was performed in 2014 by Coban[6] and has been validated 
for INH and RIF susceptibility testing. The sensitivity, 
specificity, PPV, and NPV for INH were 92.5%, 96.4%, 
96.1%, 93.1%, and 94.5% whereas they were 88.8%, 
100%, 100%, 94.8%, and 96.3% for RIF, respectively. The 
results were obtained within 8–9 days. The study concluded 
that CVDA was a rapid, simple, and inexpensive method 
for detection M. tuberculosis INH and RIF resistance in 
developing countries.[6]
Coban et al.[11] comparatively evaluated REMA, MGDA, 
microplate NRA, and CVDA for the rapid detection of 
MDR‑TB. Specificity, sensitivity, PPV, NPV, and agreement 
were 100%, 95%, 100%, 96.7%, and 98% for the INH and 
100%, 94.1%, 100%, 97%, and 98% for RIF, respectively.
Coban et al.[7] evaluated the CVDA to determine the MIC 
of primary anti‑TB drugs. It was reported that sensitivity, 
specificity, PPV, NPV, and agreement were 96.3%, 100%, 
100%, 96.3%, and 98.1% for INH; 91.3%, 100%, 100%, 93.7% 
and 96.2% for STM; and 100%, 97.6%, 90.9%, 100%, 98.1% 
for EMB, respectively. Moreover, all were 100% for RIF. The 
total agreement for the four antibiotics was obtained 98.1% 
and mean time to obtain the results was 9.5 ± 0.89 days.[7]
Recently, 11 centers participated in a multicenter study.[1] 
This study was performed in two phases. In Phase I, Center 1 
prepared the test tubes containing INH and RIF and drug‑free 
growth control tubes. These tubes were sent to all centers for 
performing drug susceptibility testing. The centers inoculated 
the bacteria into the tubes according to test procedure, and 
subsequently, they sent the tested bacteria to Center 1. The 
isolates were again tested with the same procedure in Center 
1. Agreements were 96.2%–96.8% for INH and 98.1%–98.7% 
for RIF in the Phase I and II, respectively. Mean time to obtain 
the results was 14.3 ± 5.4 days in Phase I and 11.6 ± 3.5 days 
in Phase II. The study concluded that CVDA is a rapid, safe, 
and inexpensive method and could be used for rapid detection 
of MDR‑TB. In addition, it was emphasized that it could 
be adapted for drug susceptibility testing in developed and 
developing countries.[1]
Multicenter study, especially in the determination of the 
reproducibility and reliability of the newly developed 
methods, has great importance. Especially, if the results 
of all centers are defined as the same or very close, they 
Table 1: Comparison of crystal violet decolorization assay and reference method in Phase I
Drug CVDA Reference method (BACTEC MGIT 960) Sensitivity (%) Specificity (%) PPV (%) NPV (%) Agreement (%)
R S
INH R 22 0 100 100 100 100 100
S 0 50
RIF R 16 0 100 98.2 94.1 100 98.6
S 1 55
PPV: Positive predictive value, NPV: Negative predictive value, INH: Isoniazid, RIF: Rifampicin, CVDA: Crystal violet decolorization assay, R: Resistant, 
S: Susceptible
Table 2: Comparison of crystal violet decolorization assay and reference method in Phase II
Drug CVDA Reference method (BACTEC MGIT 960) Sensitivity (%) Specificity (%) PPV (%) NPV (%) Agreement (%)
R S
INH R 21 0 100 98 95.4 100 98.6
S 1 50
RIF R 15 2 88.2 96.3 88.2 96.3 94.4
S 2 53
PPV: Positive predictive value, NPV: Negative predictive value, INH: Isoniazid, RIF: Rifampicin, CVDA: Crystal violet decolorization assay, R: Resistant, 
S: Susceptible
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provide important information regarding the reliability and 
application of the method. This is the second multicenter 
study since CVDA was developed. Coban et al.[1] performed 
the first study and the agreements were generally above 90% 
in the study. This study is a multicenter international study, 
in which the four centers participated in. The agreements 
were found to be over 90%. In this study, agreements were 
determined 100% for INH and 98.6% for RIF in Phase I. In 
Phase II, agreements were 98.6% for INH and 94.4% for 
RIF, respectively.
conclusIon
CVDA is a rapid, safe, inexpensive, and repeatable method. 
This method can be performed for susceptibility testing in 
developed and developing countries. However, further studies 
are needed with more centers and isolates.
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